Advanced Cancer Clinical Trial
Official title:
A Multicenter, Open Label,Single Arm,Phase II Study to Evaluate the Effect and Safety of Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer
Verified date | August 2019 |
Source | RemeGen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will evaluate the efficacy and safety of intravenous RC48-ADC in patients with local advanced or metastatic HER2 positive endothelial cancer.
Status | Completed |
Enrollment | 43 |
Est. completion date | October 29, 2018 |
Est. primary completion date | October 29, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: - Voluntary agreement to provide written informed consent. - Male or female, Age = 18 years and < 80 years. - Predicted survival = 12 weeks. - Have histologically or cytologically-confirmed diagnosis of inoperable, locally advanced or metastatic urothelial cancer of the bladder, renal pelvis, ureter. - Have had progression or intolerance following receipt of at least one systemic chemotherapy for advanced or metastatic disease. - Measurable disease according to RECIST 1.1. - Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1. - HER2-positive status confirmed by the central laboratory: IHC 2+ or 3+; Subject is able to provide specimens from primary or metastatic lesions for HER2 tests - Adequate organ function, evidenced by the following laboratory results: Cardiac ejection fraction = 50 %. Hemoglobin = 9g/dL; Absolute neutrophil count = 1.5×109 /L Platelets = 100×109 /L; Total bilirubin = 1.5× ULN; Without liver metastasis: ALT and AST = 2.5 x ULN; With liver metastasis: ALT and AST = 5 x ULN; Serum creatinine =1.5×ULN or creatinine clearance (CrCl) = 50 mL/min as calculated by the Cockcroft-Gault equation. - All female subjects will be considered to be of child-bearing potential unless they are postmenopausal, or have been sterilized surgically.Female subjects of child-bearing potential must agree to use two forms of highly effective contraception. Male subjects and their female partner who are of child-bearing potential must agree to use two forms of highly effective contraception. - Willing to adhere to the study visit schedule and the prohibitions and restrictions specified in this protocol. Exclusion Criteria: - Known hypersensitivity to Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection. - History of receiving any anti-cancer drug/biologic treatment within 4 weeks prior to trial treatment. - History of receiving Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection. - History of major surgery within 4 weeks of planned start of trial treatment. - Has received a live virus vaccine within 4 weeks of planned start of trial treatment. - Currently known active infection with HIV or tuberculosis. - Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator. - History of other malignancy within the previous 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or cancers with a similar curative outcome as those mentioned above. - known central nervous system metastases. - Pregnancy or lactation. - Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol. |
Country | Name | City | State |
---|---|---|---|
China | Beijing Cancer Hospital | Beijing | N/A = Not Applicable |
China | Cancer Hospital Chinese Academy of Medical Sciences | Beijing | N/A = Not Applicable |
Lead Sponsor | Collaborator |
---|---|
RemeGen |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Objective Response Rate (ORR) | Objective Response Rate was defined as the percentage of participants with a complete response (CR) or partial response (PR) | up to 24 months | |
Secondary | ORR of HER2-positive patients | Tumor response was assessed by investigator according to RECIST v1.1 | up to 24 months | |
Secondary | Progression Free Survival (PFS) | Tumor response was assessed by investigator according to RECIST v1.1 | up to 24 months | |
Secondary | Duration of Response (DOR) | DOR was defined as the time from first documented OR to first documented PD or death from any cause, whichever occurred earlier | up to 24 months | |
Secondary | Disease control rate (DCR) | DCR was defined as the proportion of patients who achieved an objective response or maintained stable disease during the study | up to 24 months | |
Secondary | Overall Survival(OS) | OS was defined as the time from the first study treatment to the date of death from any cause | up to 24 months | |
Secondary | Adverse Events | Incidence of Adverse Events | 28 days after the last dose of study treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03181854 -
Randomized Controlled Trial of Integrated Early Palliative Care
|
N/A | |
Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
Recruiting |
NCT05045040 -
Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03994601 -
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Completed |
NCT01393990 -
A Study of LY2228820 in Participants With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02857270 -
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT04121676 -
Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 | |
Active, not recruiting |
NCT03674567 -
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
|
Phase 1/Phase 2 | |
Recruiting |
NCT04823377 -
Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.
|
N/A | |
Completed |
NCT02778126 -
A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02529553 -
A Study of LY3076226 in Participants With Advanced or Metastatic Cancer
|
Phase 1 | |
Completed |
NCT02507544 -
A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02245204 -
Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers
|
Phase 1 | |
Completed |
NCT01901237 -
Yoga for Adolescent and Young Adult Non-Curative Cancer Patients
|
N/A | |
Completed |
NCT01583777 -
Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer
|
Phase 1 |